

Technology Advisory Interests Register

Topic: Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Mike Chambers	TAC Committee Member	Financial	I have participated in an advisory panel for Accord (possible comparator manufacturer) in an unrelated disease area - small-cell lung cancer.	15/05/2026	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Dr Pedro Saramago Goncalves	TAC Committee Member	Financial	I would like to declare that in the last 12 months I have worked with Vantive (a company previously owned by Baxter, which has a potential comparator for this technology appraisal) but in an unrelated indication - medical device for pulmonary ventilation. And in the last 12 months I have also worked with Boehringer Ingelheim (a company with a potential comparator for this technology appraisal) but in an unrelated indication, CKD.	19/05/2026	It was agreed that Pedro's declaration would not prevent them from participating in discussions on this appraisal
Kate Ren	TAC Committee Member	Non-financial professional	I am a member of the EAG that conducted the assessment for this topic. I had no involvement in the EAG report or internal peer-review.	19/05/2026	It was agreed that Kate's declaration would not prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Rosita Zakeri	Expert	Direct - financial	- Received payment from AstraZeneca for participation in a steering committee (non-promotional) for education of healthcare professionals on the diagnosis of HFpEF (completed; December 2023-April 2024). - Speaker payments as below (all completed): • AstraZeneca, June 2024 • AstraZeneca, November 2024 • Johnson & Johnson, March 2025 - Consultancy fee received from Boehringer Ingelheim for advice on clinical trial design (completed; September 2024). - Payment for publication in British Journal of Cardiology, Omniamed/SERB Pharmaceuticals, for an unrelated subject (history of digoxin treatment); completed September 2024.	31/10/2025	It was agreed that Rosita's declaration would not prevent them from providing expert advice to the committee
Dr Nick Hartshorne-Evans	Expert	Direct – non-financial	I am the CEO of Pumping Marvellous	29/08/2025	It was agreed that Nick's declaration would not

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			https://pumpingmarvellous.org/wp-content/uploads/2025/07/Updated-PMF-Quarterly-Report.pdf		prevent them from providing expert advice to the committee
		Indirect	I am the CEO of Pumping Marvellous https://pumpingmarvellous.org/wp-content/uploads/2025/07/Updated-PMF-Quarterly-Report.pdf		